{"id":69210,"date":"2021-04-30T03:00:21","date_gmt":"2021-04-30T01:00:21","guid":{"rendered":"https:\/\/www.cde.ual.es\/?p=69210"},"modified":"2021-09-13T10:30:00","modified_gmt":"2021-09-13T08:30:00","slug":"astrazenecas-vaccine-benefits-and-risks","status":"publish","type":"post","link":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/","title":{"rendered":"AstraZeneca\u2019s vaccine: benefits and risks"},"content":{"rendered":"<p><a href=\"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-scaled.jpg\"><img decoding=\"async\" class=\" wp-image-69211 aligncenter\" src=\"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-1024x683.jpg\" alt=\"\" width=\"362\" height=\"241\" srcset=\"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-1024x683.jpg 1024w, https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-300x200.jpg 300w, https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-768x512.jpg 768w, https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-1536x1024.jpg 1536w, https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-2048x1365.jpg 2048w\" sizes=\"(max-width: 362px) 100vw, 362px\" \/><\/a><\/p>\n<p>Vaxzevria (formerly COVID-19 Vaccine AstraZeneca) is authorised in the EU to prevent COVID-19, which can cause severe disease and death. The disease can also have long-term consequences in people of all ages, including in otherwise healthy people.<\/p>\n<p>The benefits of Vaxzevria outweigh its risks in adults of all age groups; however, very rare cases of blood clots with low blood platelets<sup>1<\/sup>\u00a0have occurred following vaccination.<\/p>\n<p>To support national authorities making decisions on how to best use the vaccine in their territories, EMA\u2019s human medicines committee\u00a0has further analysed available data to put the risk of these very rare blood clots in the context of the vaccine\u2019s benefits for different age groups and different rates of infection.<\/p>\n<p>The analysis will inform national decisions on the roll out of the vaccine, taking into account the pandemic situation as it evolves and other factors, such as vaccine availability. The analysis could change as new data become available.<\/p>\n<p>The Committee also considered available data on the use of the second dose.<\/p>\n<h3>What data show for age groups and infection rates<\/h3>\n<p>The Committee analysed the vaccine\u2019s benefits and the risk of unusual blood clots with low platelets in different age groups in the context of the monthly infection rates: low (55 per 100,000 people), medium (401 per 100,000 people) and high (886 per 100,000 people).<sup>2<\/sup><\/p>\n<p>The analysis looked at prevention of hospitalisations, ICU admissions and deaths due to COVID-19, based on different assumptions of vaccine effectiveness to contextualise the occurrence of these unusual blood clots. It showed that the benefits of vaccination increase with increasing age and infection rates.<\/p>\n<p>There were insufficient data available from across the EU to provide further context on benefits and risks with regard to sex.<\/p>\n<p><span class=\"file\">Graphic representations of the findings\u00a0<\/span>, assuming an 80% vaccine effectiveness over a period of four months, are available. The\u00a0CHMP\u2019s assessment report with the full data will be published shortly. The current analysis does not constitute an assessment of the vaccine\u2019s benefit-risk balance, which remains positive for adults in all age groups.<\/p>\n<p>As for all vaccines, Vaxzevria is approved in the EU because its benefits outweigh the risks for an individual potentially exposed to the agent causing disease. However, national authorities later consider other factors when deciding how to best use the vaccines. Because vaccination is a public health intervention, national authorities could also consider the benefits to the population as a whole, as vaccines may protect more people than are vaccinated.<\/p>\n<p>While this analysis may be subject to change as new data become available, it may guide EU Member States when they adjust their vaccination strategies depending on the infection rates and ages of people who still need to be vaccinated.<\/p>\n<h3>Second dose of Vaxzevria<\/h3>\n<p>The Committee recommended to continue giving a second dose of Vaxzevria between 4 and 12 weeks after giving the first one in line with the\u00a0product information.<\/p>\n<p>The\u00a0CHMP\u00a0considered recommendations to give the second dose of Vaxzevria after a longer interval than the recommended 4-12 weeks, to not give a second dose at all, or to give an mRNA vaccine as a second dose.<\/p>\n<p>However, there has not been enough\u00a0exposure\u00a0and follow-up time to determine\u00a0whether\u00a0the risk of blood clots with low blood platelets\u00a0after a second dose\u00a0will differ\u00a0from the risk after the first dose.\u00a0At present there are no or limited data to change current recommendations.<\/p>\n<h3>More information<\/h3>\n<p><a href=\"https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-benefits-risks-context\" target=\"_blank\" rel=\"noopener\">European Medicine Agency &#8211; Press Release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vaxzevria (formerly COVID-19 Vaccine AstraZeneca) is authorised in the EU to prevent COVID-19, which can cause severe disease and death. The disease can also have long-term consequences in people of all ages, including in otherwise healthy people. The benefits of Vaxzevria outweigh its risks in adults of all age groups; however, very rare cases of [&hellip;]<\/p>\n","protected":false},"author":101012,"featured_media":69211,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[346,4094,4092],"tags":[2598,3115,700],"class_list":{"0":"post-69210","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-eu-news","8":"category-farmac","9":"category-health","10":"tag-astrazeneca-en","11":"tag-european-medicine-agency","12":"tag-vaccine-en","13":"entry"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AstraZeneca\u2019s vaccine: benefits and risks | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca\u2019s vaccine: benefits and risks | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\" \/>\n<meta property=\"og:description\" content=\"Vaxzevria (formerly COVID-19 Vaccine AstraZeneca) is authorised in the EU to prevent COVID-19, which can cause severe disease and death. The disease can also have long-term consequences in people of all ages, including in otherwise healthy people. The benefits of Vaxzevria outweigh its risks in adults of all age groups; however, very rare cases of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/\" \/>\n<meta property=\"og:site_name\" content=\"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/cdeuniversidadalmeria\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-30T01:00:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-13T08:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BECACDE1\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@cdeualmeria\" \/>\n<meta name=\"twitter:site\" content=\"@cdeualmeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BECACDE1\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/\"},\"author\":{\"name\":\"BECACDE1\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/person\\\/bf2f837cf3353e2161fe1087adbd728f\"},\"headline\":\"AstraZeneca\u2019s vaccine: benefits and risks\",\"datePublished\":\"2021-04-30T01:00:21+00:00\",\"dateModified\":\"2021-09-13T08:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/\"},\"wordCount\":573,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/mat-napo-pIJ34ZrZEEw-unsplash-scaled.jpg\",\"keywords\":[\"AstraZeneca\",\"European Medicine Agency\",\"vaccine\"],\"articleSection\":[\"EU News\",\"Farmaceutical\",\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/\",\"name\":\"AstraZeneca\u2019s vaccine: benefits and risks | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/mat-napo-pIJ34ZrZEEw-unsplash-scaled.jpg\",\"datePublished\":\"2021-04-30T01:00:21+00:00\",\"dateModified\":\"2021-09-13T08:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/mat-napo-pIJ34ZrZEEw-unsplash-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/mat-napo-pIJ34ZrZEEw-unsplash-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/astrazenecas-vaccine-benefits-and-risks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EU News\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/category\\\/eu-news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Health\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/category\\\/eu-news\\\/health\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Farmaceutical\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/category\\\/eu-news\\\/health\\\/farmac\\\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"AstraZeneca\u2019s vaccine: benefits and risks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#website\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/\",\"name\":\"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\",\"description\":\"Centro de Documentaci\u00f3n Europea de la Universidad de Almer\u00eda\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\"},\"alternateName\":\"CDE Almer\u00eda\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cde.ual.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\",\"name\":\"Centro de Documentaci\u00f3n Europea de Almer\u00eda\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/cde-logo-3.png\",\"contentUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/cde-logo-3.png\",\"width\":1400,\"height\":300,\"caption\":\"Centro de Documentaci\u00f3n Europea de Almer\u00eda\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/cdeuniversidadalmeria\\\/\",\"https:\\\/\\\/x.com\\\/cdeualmeria\",\"https:\\\/\\\/www.tiktok.com\\\/@cdealmeria\",\"https:\\\/\\\/www.instagram.com\\\/cdealmeria\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/cde-almera-812b26a9\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/person\\\/bf2f837cf3353e2161fe1087adbd728f\",\"name\":\"BECACDE1\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"caption\":\"BECACDE1\"},\"sameAs\":[\"http:\\\/\\\/www.cdealmeria.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca\u2019s vaccine: benefits and risks | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca\u2019s vaccine: benefits and risks | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","og_description":"Vaxzevria (formerly COVID-19 Vaccine AstraZeneca) is authorised in the EU to prevent COVID-19, which can cause severe disease and death. The disease can also have long-term consequences in people of all ages, including in otherwise healthy people. The benefits of Vaxzevria outweigh its risks in adults of all age groups; however, very rare cases of [&hellip;]","og_url":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/","og_site_name":"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","article_publisher":"https:\/\/www.facebook.com\/cdeuniversidadalmeria\/","article_published_time":"2021-04-30T01:00:21+00:00","article_modified_time":"2021-09-13T08:30:00+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-scaled.jpg","type":"image\/jpeg"}],"author":"BECACDE1","twitter_card":"summary_large_image","twitter_creator":"@cdeualmeria","twitter_site":"@cdeualmeria","twitter_misc":{"Written by":"BECACDE1","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/#article","isPartOf":{"@id":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/"},"author":{"name":"BECACDE1","@id":"https:\/\/www.cde.ual.es\/#\/schema\/person\/bf2f837cf3353e2161fe1087adbd728f"},"headline":"AstraZeneca\u2019s vaccine: benefits and risks","datePublished":"2021-04-30T01:00:21+00:00","dateModified":"2021-09-13T08:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/"},"wordCount":573,"commentCount":0,"publisher":{"@id":"https:\/\/www.cde.ual.es\/#organization"},"image":{"@id":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-scaled.jpg","keywords":["AstraZeneca","European Medicine Agency","vaccine"],"articleSection":["EU News","Farmaceutical","Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/","url":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/","name":"AstraZeneca\u2019s vaccine: benefits and risks | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","isPartOf":{"@id":"https:\/\/www.cde.ual.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/#primaryimage"},"image":{"@id":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-scaled.jpg","datePublished":"2021-04-30T01:00:21+00:00","dateModified":"2021-09-13T08:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/#primaryimage","url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-scaled.jpg","contentUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/mat-napo-pIJ34ZrZEEw-unsplash-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/www.cde.ual.es\/en\/astrazenecas-vaccine-benefits-and-risks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.cde.ual.es\/en\/"},{"@type":"ListItem","position":2,"name":"EU News","item":"https:\/\/www.cde.ual.es\/en\/category\/eu-news\/"},{"@type":"ListItem","position":3,"name":"Health","item":"https:\/\/www.cde.ual.es\/en\/category\/eu-news\/health\/"},{"@type":"ListItem","position":4,"name":"Farmaceutical","item":"https:\/\/www.cde.ual.es\/en\/category\/eu-news\/health\/farmac\/"},{"@type":"ListItem","position":5,"name":"AstraZeneca\u2019s vaccine: benefits and risks"}]},{"@type":"WebSite","@id":"https:\/\/www.cde.ual.es\/#website","url":"https:\/\/www.cde.ual.es\/","name":"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","description":"Centro de Documentaci\u00f3n Europea de la Universidad de Almer\u00eda","publisher":{"@id":"https:\/\/www.cde.ual.es\/#organization"},"alternateName":"CDE Almer\u00eda","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cde.ual.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cde.ual.es\/#organization","name":"Centro de Documentaci\u00f3n Europea de Almer\u00eda","url":"https:\/\/www.cde.ual.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cde.ual.es\/#\/schema\/logo\/image\/","url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2025\/07\/cde-logo-3.png","contentUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2025\/07\/cde-logo-3.png","width":1400,"height":300,"caption":"Centro de Documentaci\u00f3n Europea de Almer\u00eda"},"image":{"@id":"https:\/\/www.cde.ual.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/cdeuniversidadalmeria\/","https:\/\/x.com\/cdeualmeria","https:\/\/www.tiktok.com\/@cdealmeria","https:\/\/www.instagram.com\/cdealmeria\/","https:\/\/www.linkedin.com\/in\/cde-almera-812b26a9\/"]},{"@type":"Person","@id":"https:\/\/www.cde.ual.es\/#\/schema\/person\/bf2f837cf3353e2161fe1087adbd728f","name":"BECACDE1","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","caption":"BECACDE1"},"sameAs":["http:\/\/www.cdealmeria.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts\/69210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/users\/101012"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/comments?post=69210"}],"version-history":[{"count":0,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts\/69210\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/media\/69211"}],"wp:attachment":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/media?parent=69210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/categories?post=69210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/tags?post=69210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}